UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR (UPAR)-PET/CT IN HEAD AND NECK SQUAMOUS CELL CARCINOMAS (HNSCCS)

The present invention relates to the a positron-emitting imaging agent for use in the prognosis of a head and neck cancer (HNSCC) in a subject by PET imaging of the cancer, wherein said imaging agent comprises a uPAR bindingpeptide coupled via the chelating agent NOTA or DOTA to the radionuclide 568...

Full description

Saved in:
Bibliographic Details
Main Author KJÆR, Andreas
Format Patent
LanguageEnglish
French
Published 08.06.2023
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention relates to the a positron-emitting imaging agent for use in the prognosis of a head and neck cancer (HNSCC) in a subject by PET imaging of the cancer, wherein said imaging agent comprises a uPAR bindingpeptide coupled via the chelating agent NOTA or DOTA to the radionuclide 568Ga or 64Cu. La présente invention concerne un agent d'imagerie émetteur de positons pour une utilisation dans le pronostic d'un cancer de la tête et du cou (HNSCC) chez un sujet par imagerie PET du cancer, ledit agent d'imagerie comprenant un peptide de liaison à l'uPAR couplé par l'intermédiaire de l'agent chélatant NOTA ou DOTA au radionucléide 568Ga ou 64Cu.
Bibliography:Application Number: WO2022EP83665